Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML).

NCT01916785 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.

NCT NCT01916785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01916785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML).
Lead sponsor
Versailles Hospital
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
December 31, 2013
Enrollment
289 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia, bcr/abl positive